Upcoming Events
Title: Johnson & Johnson Second Quarter 2012 Earnings Conference Call
Date: Jul 17, 2012
8:30 AM
Remind me
Please sign up for
Title: Johnson & Johnson Third Quarter 2012 Earnings Conference Call
Date: Oct 16, 2012
8:30 AM
Remind me
Title: Johnson & Johnson Medical Devices & Diagnostics Business Review
Date: Nov 1, 2012
8:30 AM
Remind me
Archived Events
Title: Johnson & Johnson at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference
Date: May 9, 2012
10:40 AM
Speaker(s): Dominic J. Caruso, Vice President, Finance and Chief Financial Officer
Click here to view to the webcast.
Podcast
Title: Johnson & Johnson Annual Meeting of Shareholders
Date: Apr 26, 2012
10:00 AM
Click here to view to the webcast.
Listen to Webcast
Podcast
Title: Johnson & Johnson First Quarter 2012 Earnings Conference Call
Date: Apr 17, 2012
8:30 AM ET
Click here to view to the webcast.
Podcast
Title: EINSTEIN PE Data Summary & Perspectives on XARELTO® (rivaroxaban) in ORS & NVAF: Recorded Webcast Update for Analysts and Investors
Date: Mar 26, 2012
10:30 AM ET
Click here to view to the webcast.
Podcast
Title: Johnson & Johnson and Synthes Announce Definitive Merger Agreement Conference Call
Date: Apr 27, 2011
8:30 AM ET
Speaker(s): Louise Mehrotra, Vice President, Investor Relations, Johnson & Johnson
William C. Weldon, Chairman, Board of Directors and Chief Executive Officer, Johnson & Johnson
Hansjoerg Wyss, Founder and Chairman of the Board, Synthes
Alex Gorsky, Vice Chairman, Executive Committee, Office of the Chairman, Johnson & Johnson
Michel Orsinger, President and Chief Executive Officer, Synthes
Dominic Caruso, Vice President Finance and Chief Financial Officer, Johnson & Johnson
Mike Mahoney, Worldwide Chairman, Medical Devices & Diagnostics; Johnson & Johnson
Click here to view to the webcast.
Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create World's Most Innovative and Comprehensive Orthopaedics Business
Podcast
Additional Information and Where to Find It
Johnson & Johnson will file with the SEC a registration statement on Form S-4, in which a proxy statement will be included as a prospectus, and other documents in connection with the proposed acquisition of Synthes. The proxy statement/prospectus will be sent to the stockholders of Synthes. Before making any decision with respect to the proposed transaction, stockholders of Synthes are urged to read the proxy statement/prospectus and other relevant materials because these materials will contain important information about the proposed transaction. The registration statement and proxy statement/prospectus and other documents which will be filed by Johnson & Johnson with the SEC will be available free of charge at the SEC's website, www.sec.gov, or by directing a request to Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933, Attention: Investor Relations; or by directing a request to Synthes, Inc., c/o Synthes Gmbh, Glutz-Blotzheim-Strasse 3, 4500 Solothurn, Switzerland, Attention: Investor Relations. Certain executive officers and directors of Synthes have interests in the proposed transaction that may differ from the interests of stockholders generally, including benefits conferred under retention, severance and change in control arrangements and continuation of director and officer insurance and indemnification.
This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction.
(This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson and Synthes, Inc. Risks and uncertainties include, but are not limited to, the satisfaction of closing conditions for the acquisition, including receipt of regulatory approvals for the transaction, receipt of approval by the shareholders of Synthes for the transaction, and the possibility that the transaction will not be completed, or if completed, will not be completed on a timely basis; general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to Johnson & Johnson's ability to successfully integrate the products and employees of Johnson & Johnson and Synthes, as well as the ability to ensure continued performance or market growth of Synthes' products. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Synthes can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011, and Synthes' Annual Report 2010. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.synthes.com or on request from Johnson & Johnson or Synthes. Neither Johnson & Johnson nor Synthes undertakes to update any forward-looking statements as a result of new information or future events or developments.)